Morgan Stanley resumed coverage of Ovintiv with a rating of Equal-Weight and set a new price target of $44.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/26/2025 | $57.00 | Overweight | Morgan Stanley |
| 3/24/2025 | $55.00 → $57.00 | Market Perform → Outperform | BMO Capital Markets |
| 1/13/2025 | $55.00 → $54.00 | Neutral → Buy | BofA Securities |
| 7/18/2024 | $65.00 | Outperform | Wolfe Research |
| 6/14/2024 | $60.00 | In-line → Outperform | Evercore ISI |
| 4/10/2024 | $69.00 | Overweight | Barclays |
| 12/6/2023 | $61.00 → $58.00 | Neutral → Overweight | JP Morgan |
| 11/22/2023 | $48.00 → $52.00 | Neutral → Buy | Citigroup |
Morgan Stanley resumed coverage of Ovintiv with a rating of Overweight and set a new price target of $57.00
BMO Capital Markets upgraded Ovintiv from Market Perform to Outperform and set a new price target of $57.00 from $55.00 previously
BofA Securities upgraded Ovintiv from Neutral to Buy and set a new price target of $54.00 from $55.00 previously